Bone Therapeutics Granted an Additional EUR 2 Million in Non-Dilutive Funding by the Walloon Region Read more about Bone Therapeutics Granted an Additional EUR 2 Million in Non-Dilutive Funding by the Walloon Region
Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2016 Read more about Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2016
Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures Read more about Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures
Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2016 Read more about Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2016
Bone Therapeutics extends Kasios collaboration Read more about Bone Therapeutics extends Kasios collaboration
Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial Read more about Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial
Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015 Read more about Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015
Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference Read more about Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference
Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016 Read more about Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016
Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis Read more about Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis